QT Imaging Granted Renewal of NIH Sponsored Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy
Research Grant Renewal: QT Imaging Holdings, Inc. has received a third-year renewal of its five-year research grant from the NIH/NCI to develop a portable breast imaging system aimed at early detection of cancer treatment responses in patients undergoing neoadjuvant chemotherapy.
Innovative Imaging Techniques: The project utilizes the QTI Breast Acoustic CT™ System for high-resolution imaging and aims to integrate AI/ML techniques to enhance the estimation of treatment efficacy based on newly available quantitative biomarkers.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on QTI
About QTI
About the author
QT Imaging Holdings Introduces Machine Learning-Enabled Image Interpolation Algorithm to Substantially Reduce Scan Time
New Machine Learning Algorithm: QT Imaging Holdings, Inc. has introduced a machine learning-enabled image interpolation algorithm that reduces scan times by approximately 50%, enhancing patient comfort and operational efficiency in medical imaging.
Commitment to Innovation: The company aims to improve health outcomes through safe, affordable, and accessible medical imaging, collaborating with leading institutions to advance cancer detection and treatment technologies.
QT Imaging Holdings Announces Clearing of All Its Short-Term Liabilities and Forecasts Solid Revenue Growth
Financial Strengthening: QT Imaging Holdings, Inc. has improved its financial position by clearing short-term liabilities and expects significant revenue growth, forecasting $18M in 2025 and $27M in 2026, alongside amendments to its convertible promissory notes that defer payments until March 31, 2026.
Company Overview: QT Imaging is a public medical device company focused on innovative body imaging systems using low-frequency sound waves, aiming to enhance global health outcomes through safe and accessible medical imaging solutions.